Study of the effects of interferon β-1a on hospitalized patients with COVID-19 : SBMU Taskforce on the COVIFERON study
© 2021 Wiley Periodicals LLC..
Interferons are an essential part of the innate immune system and have antiviral and immunomodulatory functions. We studied the effects of interferon β-1a on the outcomes of severe cases of coronavirus disease 2019 (COVID-19). This retrospective study was conducted on hospitalized COVID-19 patients in Loghman-Hakim hospital from February 20, 2020 to April 20, 2020, Tehran, Iran. Patients were selected from two groups, the first group received interferon β-1a in addition to the standard treatment regimen, and the second group received standard care. The clinical progression of two groups during their hospital admission was compared. We studied a total number of 395 hospitalized COVID-19 patients. Out of this number, 111 patients (33.5%) died (31.3% of the interferon β-1a group and 34.1% of the control group). The mortality rate indicated no statistically significant difference between groups (p-value = 0.348), however for patients who were hospitalized for more than a week, the rate of mortality was lower in the interferon β-1a group (p-value = 0.014). The median hospital stay was statistically longer for patients treated by interferon β-1a (p-value < 0.001). The results of this study showed that interferon β-1a can improve the outcomes of hospitalized patients with severe COVID-19, but more adequately-powered randomized controlled trials should be conducted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Journal of medical virology - 94(2022), 4 vom: 01. Apr., Seite 1488-1493 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fallahzadeh, Mohammad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 04.03.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.27475 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333585518 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333585518 | ||
| 003 | DE-627 | ||
| 005 | 20231225221939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.27475 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333585518 | ||
| 035 | |a (NLM)34821387 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fallahzadeh, Mohammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Study of the effects of interferon β-1a on hospitalized patients with COVID-19 |b SBMU Taskforce on the COVIFERON study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a Interferons are an essential part of the innate immune system and have antiviral and immunomodulatory functions. We studied the effects of interferon β-1a on the outcomes of severe cases of coronavirus disease 2019 (COVID-19). This retrospective study was conducted on hospitalized COVID-19 patients in Loghman-Hakim hospital from February 20, 2020 to April 20, 2020, Tehran, Iran. Patients were selected from two groups, the first group received interferon β-1a in addition to the standard treatment regimen, and the second group received standard care. The clinical progression of two groups during their hospital admission was compared. We studied a total number of 395 hospitalized COVID-19 patients. Out of this number, 111 patients (33.5%) died (31.3% of the interferon β-1a group and 34.1% of the control group). The mortality rate indicated no statistically significant difference between groups (p-value = 0.348), however for patients who were hospitalized for more than a week, the rate of mortality was lower in the interferon β-1a group (p-value = 0.014). The median hospital stay was statistically longer for patients treated by interferon β-1a (p-value < 0.001). The results of this study showed that interferon β-1a can improve the outcomes of hospitalized patients with severe COVID-19, but more adequately-powered randomized controlled trials should be conducted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a IFN-β1a | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a outcome | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon beta-1a |2 NLM | |
| 650 | 7 | |a XRO4566Q4R |2 NLM | |
| 700 | 1 | |a Pourhoseingholi, Mohamad A |e verfasserin |4 aut | |
| 700 | 1 | |a Boroujeni, Masoud G |e verfasserin |4 aut | |
| 700 | 1 | |a Besharati, Sajad |e verfasserin |4 aut | |
| 700 | 1 | |a Mardani, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Shabani, Minoosh |e verfasserin |4 aut | |
| 700 | 1 | |a Shokouhi, Shervin |e verfasserin |4 aut | |
| 700 | 1 | |a Amirdosara, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Hajiesmaeili, Mohammadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Gachkar, Latif |e verfasserin |4 aut | |
| 700 | 1 | |a Roshan, Baran |e verfasserin |4 aut | |
| 700 | 1 | |a Zangi, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Mirmomeni, Golshan |e verfasserin |4 aut | |
| 700 | 1 | |a Irvani, Seyed S N |e verfasserin |4 aut | |
| 700 | 1 | |a Alavi Darazam, Ilad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 94(2022), 4 vom: 01. Apr., Seite 1488-1493 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:1488-1493 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.27475 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2022 |e 4 |b 01 |c 04 |h 1488-1493 | ||